Following this appointment, Thomas Hudson, currently senior vice president and chief scientific officer of global research at AbbVie, will retire.
Credit: Skorzewiak / Shutterstock.com
Dr. Roopal Thakkar has been appointed Executive Vice President of Research and Development and Chief Scientific Officer of AbbVie.
He is the companyCurrent Senior Vice President and Chief Medical Officer of Global Therapeutics.
“As AbbVie’s chief scientific officer, Dr. Thakkar will continue to drive the discovery process and all stages of development to fully realize the potential of our diverse product portfolio. He has the right vision, skills and experience to lead our R&D organization,” said Rob Michael, CEO of AbbVie. Michael assumed his new role earlier this month, following the announcement of his CEO position in February of this year.
AbbVie’s new chief scientific officer
As AbbVie’s chief scientific officer, Dr. Thakkar will continue to drive discovery and all stages of development to realize the full potential of our diverse pipeline.”
“I am excited to take on these new responsibilities within AbbVie’s R&D organization,” said Roopal Thakkar, Ph.D., Executive Vice President, Research and Development and Chief Scientific Officer, AbbVie. “Our portfolio of more than 90 drug and device programs represents a significant opportunity to secure AbbVie’s growth over the next decade… and it is my privilege to lead this organization as we address patients’ most challenging health problems.”
AbbVie’s current senior vice president and global chief scientific officer for research, Thomas Hudson, will retire. He joined AbbVie in 2016 and was appointed chief scientific officer in 2019.
Previous positions of Dr. Thakkar
As AbbVie’s executive vice president of research and development and chief scientific officer, Dr. Thakkar is also responsible for AbbVie’s six core R&D centers of excellence located in the United States, Germany and Japan, AbbVie shared.
Dr. Thakkar joined Abbott/AbbVie in 2003 and has progressed through several positions in clinical development, including Group Project Director, Immunology, as well as Vice President, Global Regulatory Affairs.
In 2019, Dr. Thakkar assumed the role of Vice President, Global Regulatory Affairs and Quality Assurance, R&D. In 2022, he was appointed Senior Vice President, Regulatory Affairs and Development and Chief Medical Officer. Last year, Dr. Thakkar assumed the role of Senior Vice President and Chief Medical Officer, Global Therapeutics.
He trained in internal medicine and was a clinical fellow at the University of Alabama, Birmingham, and Wake Forest University School of Medicine. Dr. Thakkar earned his bachelor’s degree in cellular and molecular biology from the University of Michigan and his MD from Wayne State University School of Medicine, USA.
JOBs Apply News
For the Latest JOBs Apply News, Follow ©JOBs Apply News on Twitter and Linkedin Page.
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/archetype/XOH6XFHAS5DKHBCVZX2LUKA6X4.jpg?w=150&resize=150,150&ssl=1 "GAO union employees retain flexible work options in new contract| JOBs News")
